Previous Close | 74.05 |
Open | 75.57 |
Bid | 72.00 x 1200 |
Ask | 76.01 x 900 |
Day's Range | 70.33 - 76.98 |
52 Week Range | 56.51 - 232.76 |
Volume | |
Avg. Volume | 570,748 |
Market Cap | 8.007B |
Beta (5Y Monthly) | 0.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.27 |
Earnings Date | Apr 27, 2022 - May 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 104.57 |
Does the May share price for NovoCure Limited ( NASDAQ:NVCR ) reflect what it's really worth? Today, we will estimate...
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the “Board”). On May 11, 2022, the Board appointe
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Ginkgo Bioworks Holdings (NYSE: DNA), and Novocure (NASDAQ: NVCR). Prosper Junior Bakiny (CRISPR Therapeutics): "Beaten-down" doesn't begin to describe what has happened to CRISPR Therapeutics in the past year on the market. CRISPR Therapeutics has several promising pipeline candidates.